These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 27862167)
1. The effect of inflammation on voriconazole trough concentrations in children. Ter Avest M; Veringa A; van den Heuvel ER; Kosterink JG; Schölvinck EH; Tissing WJ; Alffenaar JC Br J Clin Pharmacol; 2017 Mar; 83(3):678-680. PubMed ID: 27862167 [No Abstract] [Full Text] [Related]
2. Inflammation is associated with voriconazole trough concentrations. van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China. Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190 [TBL] [Abstract][Full Text] [Related]
6. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898 [TBL] [Abstract][Full Text] [Related]
7. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512 [No Abstract] [Full Text] [Related]
8. Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients. Luo X; Li T; Hu L; Liu S; Zhao H; Zhang J; Feng Y; Huang L J Chemother; 2021 Apr; 33(2):95-105. PubMed ID: 32441568 [TBL] [Abstract][Full Text] [Related]
9. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158 [TBL] [Abstract][Full Text] [Related]
11. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis? Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Liu P; Mould DR Antimicrob Agents Chemother; 2014 Aug; 58(8):4727-36. PubMed ID: 24914120 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Allegra S; Fatiguso G; De Francia S; Favata F; Pirro E; Carcieri C; De Nicolò A; Cusato J; Di Perri G; D'Avolio A Br J Clin Pharmacol; 2018 Jan; 84(1):197-203. PubMed ID: 28805964 [TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib. Nyga R; Simon L; Chouaki T; Delette C; Bennis Y; Joseph C; Marolleau JP; Slama M; Zogheib E; Maizel J Crit Care; 2019 Mar; 23(1):88. PubMed ID: 30866996 [No Abstract] [Full Text] [Related]
16. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients. Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292 [TBL] [Abstract][Full Text] [Related]
17. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy. Kadam RS; Van Den Anker JN Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736 [TBL] [Abstract][Full Text] [Related]
18. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. Kato K; Nagao M; Yamamoto M; Matsumura Y; Takakura S; Fukuda K; Ichiyama S J Infect Chemother; 2016 Jan; 22(1):27-31. PubMed ID: 26538245 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Encalada Ventura MA; van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW Antimicrob Agents Chemother; 2016 May; 60(5):2727-31. PubMed ID: 26883707 [TBL] [Abstract][Full Text] [Related]
20. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision? Zhong X; Tong X; Ju Y; Du X; Li Y Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]